ORIC Pharmaceuticals, Inc. (ORIC) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
ORIC EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ORIC Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export ORIC earnings history in CSV or JSON format
Free sign-in required to download data
ORIC Pharmaceuticals, Inc. (ORIC) Earnings Overview
As of May 8, 2026, ORIC Pharmaceuticals, Inc. (ORIC) reported trailing twelve-month net income of -$135M, reflecting +19.7% year-over-year growth. The company earned $-1.28 per diluted share over the past four quarters.
Looking at the long-term picture, ORIC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$21M in fiscal 2018.
ORIC Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), TNGX (-$102M net income, -162.9% margin), PRAX (-$327M net income), ORIC has comparable earnings metrics. Compare ORIC vs KYMR →
ORIC Earnings vs Peers
Earnings metrics vs comparable public companies
ORIC Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$129M | -1.3% | -$143M | $-1.47 | - | - |
| 2024 | -$128M | -27.0% | -$143M | $-1.83 | - | - |
| 2023 | -$101M | -13.0% | -$111M | $-1.96 | - | - |
| 2022 | -$89M | -13.2% | -$92M | $-2.25 | - | - |
| 2021 | -$79M | -6.8% | -$79M | $-2.07 | - | - |
| 2020 | -$74M | -174.2% | -$74M | $-3.36 | - | - |
| 2019 | -$27M | -25.8% | -$29M | $-1.40 | - | - |
| 2018 | -$21M | +3.0% | -$22M | $-12.32 | - | - |
| 2017 | -$22M | - | -$23M | $-15.62 | - | - |
See ORIC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ORIC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ORIC vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonORIC — Frequently Asked Questions
Quick answers to the most common questions about buying ORIC stock.
Is ORIC growing earnings?
ORIC EPS is $-1.28, with earnings growth accelerating to +19.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-135M.
What are ORIC's profit margins?
ORIC Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ORIC's earnings?
ORIC earnings data spans 2017-2025. The accelerating earnings trend is +19.7% YoY. Historical data enables comparison across business cycles.